key: cord-0844886-u8gxhcwp authors: Krammer, Florian; Srivastava, Komal; Alshammary, Hala; Amoako, Angela A.; Awawda, Mahmoud H.; Beach, Katherine F.; Bermúdez-González, Maria C.; Bielak, Dominika A.; Carreño, Juan M.; Chernet, Rachel L.; Eaker, Lily Q.; Ferreri, Emily D.; Floda, Daniel L.; Gleason, Charles R.; Hamburger, Joshua Z.; Jiang, Kaijun; Kleiner, Giulio; Jurczyszak, Denise; Matthews, Julia C.; Mendez, Wanni A.; Nabeel, Ismail; Mulder, Lubbertus C.F.; Raskin, Ariel J.; Russo, Kayla T.; Salimbangon, Ashley-Beathrese T.; Saksena, Miti; Shin, Amber S.; Singh, Gagandeep; Sominsky, Levy A.; Stadlbauer, Daniel; Wajnberg, Ania; Simon, Viviana title: Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine date: 2021-03-10 journal: N Engl J Med DOI: 10.1056/nejmc2101667 sha: 4d3c4aa9a0819461f10cf71e626959f205def5f8 doc_id: 844886 cord_uid: u8gxhcwp nan . The antibody titers of vaccinees with preexisting immunity were 10 to 45 times as high as those of vaccinees without preexisting immunity at the same time points after the first vaccine dose (e.g., 25 times as high at 13 to 16 days) and also exceeded the median antibody titers measured in participants without preexisting immunity after the second vaccine dose by more than a factor of 6. Although the antibody titers of the vaccinees without preexisting immunity increased by a factor of 3 after the second vaccine dose, no increase in antibody titers was observed in the Covid-19 survivors who received the second vaccine dose. No substantial difference was noted in the dynamics of antibody responses elicited by the Pfizer and Moderna vaccines after the first dose (Fig. S1 ). The current analysis represents a convenience sample in which not all participants were able to provide biospecimens for antibody analysis at all the additional time intervals. Ongoing follow-up studies will show whether these early differences in immune responses are maintained over a prolonged time period. In addition, we compared the frequency of local, injection-site-related as well as systemic reactions after the first dose of vaccine in 230 participants ( (Fig. 1B) . Overall, both vaccines (156 participants received the Pfizer vaccine and 74 the Moderna vaccine) had no side effects that resulted in hospitalization. A total of 159 of the 230 participants (69%) who completed the PARIS study survey reported having some side effects after the first vaccine dose (46% of the seronegative survey respondents and 89% of the seropositive survey respondents). Most common were localized injection-site symptoms (pain, swelling, and erythema), which occurred with equal frequency independently of the serostatus at the time of vaccination and resolved spontaneously within days after vaccination. Vaccine recipients with preexisting immunity had systemic side effects at higher frequencies than those without preexisting immunity (fatigue, headache, chills, Panel A shows the quantitative SARS-CoV-2 spike antibody titers (assessed by means of enzyme-linked immunosorbent assay and expressed as area under the curve [AUC]) for 110 participants. Some participants with preexisting immunity had antibody titers below detection (AUC of 1) at the time point before vaccination. Geometric means with 95% confidence intervals (not adjusted for multiple testing) are shown. Panel B shows the relative frequency of vaccine-associated side effects after the first vaccine dose (230 participants). The local side effects occurred with similar frequency among participants with preexisting immunity and among those without preexisting immunity, whereas the systemic symptoms were more common among participants with preexisting immunity. The bars represent the relative frequency of each symptom, and the numbers at the top of the graph represent the absolute numbers for a given symptom, with a given participant possibly having more than one symptom. 67 43 12 7 22 15 13 8 18 20 21 4 19 14 36 19 98 86 14 10 37 27 10 14 7 6 8 61 56 3 42 31 25 24 11 19 muscle pain, fever, and joint pain, in order of decreasing frequency) (Fig. 1B) . Because a convenience sample was used and only participants with available data were studied, caution is needed until the full data set, including side effects occurring after the first as well as the second vaccine dose, can be assessed. We found that a single dose of mRNA vaccine elicited rapid immune responses in seropositive participants, with postvaccination antibody titers that were similar to or exceeded titers found in seronegative participants who received two vaccinations. Whether a single dose of mRNA vaccine provides effective protection in seropositive per- edu viviana . simon@ mssm . edu Supported by the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (contract 75N93019C00051), the NIAID Centers of Excellence for Influenza Research and Surveillance (contract HHSN272201400008C), the JPB Foundation, the Open Philanthropy Project SARS-CoV-2 vaccines in development Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City Correspondence Copyright © 2021 Massachusetts Medical Society